Chemotherapy + Imatinib · Oncology This combination uses chemotherapy to kill rapidly dividing cancer cells while imatinib inhibits BCR-ABL and other tyrosine kinases to block leukemic cell proliferation and survival.
Cytarabine HD · Oncology Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.
DaunoXome · Oncology DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells.
Ponatinib + Blinatumomab · Oncology Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.
Phase 2 pipeline
Antibiotic and antifungal drugs · Infectious Diseases Antibiotic and antifungal drugs work by inhibiting bacterial cell wall synthesis and interfering with fungal cell membrane function.
Cycle 1 Induction · Oncology Cycle 1 Induction is a chemotherapy regimen used in hematologic malignancies to induce remission through cytotoxic drug combinations.
Dasatinib and blinatumomab · Oncology Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.
High-dose anthracycline · Oncology anthracyclines intercalate DNA strands, inhibiting topoisomerase II